Form 4: Akero Therapeutics Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 637 shares of common stock on September 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On September 10, 2024, Catriona Yale, the Chief Development Officer of Akero Therapeutics, sold 637 shares of the company's common stock.
- The sale was executed at a price of $26.18 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Yale directly owns 75,294 shares of Akero Therapeutics common stock.
- The sale was automatic under Akero Therapeutics' 'sell-to-cover' policy and not at the discretion of the reporting person.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sell-to-cover) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction reflects standard compensation practices and tax management strategies.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of the stock sale transaction. |
| 09/13/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.